How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

101,779 results for

Pharmaceutical Representative

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. A Randomized Clinical Trial of Family Therapy in Juvenile Drug Court. Full Text available with Trip Pro

A Randomized Clinical Trial of Family Therapy in Juvenile Drug Court. The objective of this article is to examine the effectiveness of 2 theoretically different treatments delivered in juvenile drug court--family therapy represented by multidimensional family therapy (MDFT) and group-based treatment represented by adolescent group therapy (AGT)--on offending and substance use. Intent-to-treat sample included 112 youth enrolled in juvenile drug court (primarily male [88%], and Hispanic [59 (...) %] or African American [35%]), average age 16.1 years, randomly assigned to either family therapy (n = 55) or group therapy (n = 57). Participants were assessed at baseline and 6, 12, 18 and 24 months following baseline. During the drug court phase, youth in both treatments showed significant reduction in delinquency (average d = .51), externalizing symptoms (average d = 2.32), rearrests (average d = 1.22), and substance use (average d = 4.42). During the 24-month follow-up, family therapy evidenced greater

2015 Journal of family psychology : JFP : journal of the Division of Family Psychology of the American Psychological Association (Division 43) Controlled trial quality: uncertain

102. Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice. Full Text available with Trip Pro

Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice. Heart failure represents a primary cause of morbidity and mortality in older people and despite significant therapeutic advances, it is still characterized by important unmet needs, thus remaining a challenging field of clinical research. The recent PARADIGM-HF trial compared the novel compound LCZ696, a combination of the angiotensin (...) of a cornerstone of current heart failure therapy, the angiotensin-converting enzyme inhibitors, should follow careful steps as imposed by the study design, the recruited population and the outcome in specific patient subgroups. Further insights into the effects of LCZ696 will be provided by the ongoing PARAGON-HF trial in patients with diastolic heart failure.

2015 BMC Medicine

103. In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia Full Text available with Trip Pro

In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia The mechanism of therapeutic efficacy of flecainide for catecholaminergic polymorphic ventricular tachycardia (CPVT) is unclear. Model predictions suggest that Na(+) channel effects are insufficient to explain flecainide efficacy in CPVT. This study represents a first step toward predicting therapeutic mechanisms of drug efficacy in the setting of CPVT and then using these mechanisms to guide modelling (...) and simulation to predict alternative drug therapies. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterized by fatal ventricular arrhythmias in structurally normal hearts during β-adrenergic stimulation. Current treatment strategies include β-blockade, flecainide and ICD implementation--none of which is fully effective and each comes with associated risk. Recently, flecainide has gained considerable interest in CPVT treatment, but its mechanism

2015 The Journal of physiology

104. Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis

) Primary Purpose: Treatment Official Title: Comparison of Combination Disease Modifying Antirheumatic Drugs (DMARDs) With Single Drug (Methotrexate) Therapy in Early Rheumatoid Arthritis Actual Primary Completion Date : November 17, 2016 Actual Study Completion Date : February 27, 2017 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Combination therapy Combination (...) Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2015 Clinical Trials

105. Safety and Efficacy of Left Atrial Appendage Closure Versus Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Due to Complex Coronary Artery Disease

University Study Details Study Description Go to Brief Summary: Comparatively analyze the safety and validity of Amplazter Cardiac Plug (ACP) device-using percutaneous left atrial appendage closure, and the medical treatment with dabigatran plus aspirin or dabigatran plus clopidogrel after 3months triple therapy (Dabigatran plus DAPT (dual-antiplatelet therapy)) in patient with coronary artery disease treated with drug-eluting stent, accompanying atrial fibrillation. Total of 670 patients [left atrial (...) : related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Dabigatran plus aspirin Medical treatment with dabigatran plus aspirin after 3months triple therapy (Dabigatran plus DAPT (dual-antiplatelet therapy)) Drug: Dabigatrain plus aspirin Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation. Aspirin is indicated for the prevention of stent thrombosis

2015 Clinical Trials

106. Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir Full Text available with Trip Pro

Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir A 66-year-old, interferon-ineligible, treatment-naive man who was diagnosed with chronic hepatitis C due to hepatitis C virus genotype 1b began combination therapy with daclatasvir and asunaprevir. On day 14 of treatment, hepatic reserve and renal function deterioration was observed, while his transaminase levels were normal. Both daclatasvir and asunaprevir (...) were discontinued on day 18 of treatment, because the patient complained of dark urine and a rash on his trunk and four limbs. After discontinuing antiviral therapy, the abnormal laboratory finding and clinical manifestations gradually improved, without recurrence. Our case fulfilled the diagnostic criteria of probable drug reaction with eosinophilia and systemic symptom (DRESS) syndrome. Despite the 18-d treatment, sustained virological response 12 was achieved. Based on the clinical course, we

2015 World journal of clinical cases

107. HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection

in harm reduction strategies. Our intent is to evaluate study participants who are representative of our clinical population and consider 'difficult to cure' compared to populations already evaluated in licensing studies Exclusion: Concomitant use of drugs with contraindication drug interactions with E/C/F/TAF of SOF-LDV History of HIV integrase inihbitors or NRTI resistance mutations Platelets <50 x109/L Contacts and Locations Go to Information from the National Library of Medicine To learn more (...) HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. HIV Drug Switch Followed

2015 Clinical Trials

108. Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Anti-Inflammatory (...) Small Drug Adjunctive Therapy for Type 2 Diabetes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02597101 Recruitment Status : Active, not recruiting First Posted : November 5, 2015 Last Update Posted : May 21, 2018 Sponsor: Nick Giannoukakis, PhD Collaborators: National Institutes of Health (NIH

2015 Clinical Trials

109. The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly. Full Text available with Trip Pro

The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly. Infectious diseases are more prevalent in older people than in younger adults, and represent a major healthcare issue in older populations. Indeed, infections in the elderly are often associated with higher morbidity and mortality, and may present atypically. Additionally, older patients are generally treated with polypharmacy regimens, which increase the likelihood of drug-drug interactions when (...) the prescription of an antimicrobial agent is needed. A progressive impairment in the functional reserve of multiple organs may affect either pharmacokinetics or pharmacodynamics during aging. Changes in body composition occurring with advancing age, reduced liver mass and perfusion, and reduced renal excretion may affect either pharmacokinetics or pharmacodynamics. These issues need to be taken into account when prescribing antimicrobial agents to older complex patients taking multiple drugs. Interventions

2015 Clinical Microbiology and Infection

110. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs Full Text available with Trip Pro

Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs For human immunodeficiency virus (HIV)-infected patients, the 1990s were marked by the introduction of highly active antiretroviral therapy (HAART) representing a new perspective of life for these patients. The use of HAART was shown to effectively suppress the replication of HIV-1 and dramatically reduce mortality and morbidity, which led to a better and longer quality (...) of life for HIV-1-infected patients. Apart from the substantial benefits that result from the use of various HAART regimens, laboratory and clinical experience has shown that HAART can induce severe and considerable adverse effects related to metabolic complications of lipid metabolism, characterized by signs of lipodystrophy, insulin resistance, central adiposity, dyslipidemia, increased risk of cardiovascular disease and even an increased risk of atherosclerosis. New drugs are being studied, new

2015 World journal of virology

111. Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis Full Text available with Trip Pro

Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis African trypanosomiasis is a deadly neglected disease caused by the extracellular parasite Trypanosoma brucei. Current therapies are characterized by high drug toxicity and increasing drug resistance mainly associated with loss-of-function mutations in the transporters involved in drug import. The introduction of new antiparasitic drugs into therapeutic use is a slow and expensive process. In contrast (...) , specific targeting of existing drugs could represent a more rapid and cost-effective approach for neglected disease treatment, impacting through reduced systemic toxicity and circumventing resistance acquired through impaired compound uptake. We have generated nanoparticles of chitosan loaded with the trypanocidal drug pentamidine and coated by a single domain nanobody that specifically targets the surface of African trypanosomes. Once loaded into this nanocarrier, pentamidine enters trypanosomes

2015 PLoS pathogens

112. Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons

Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons (SENATOR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02097654 Recruitment Status : Completed

2014 Clinical Trials

113. Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome

Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome (FMSRCT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03325959 Recruitment Status : Not yet recruiting First Posted : October 30

2017 Clinical Trials

114. Cellular and Molecular Mechanisms Underlying Non-Pharmaceutical Ischemic Stroke Therapy in Aged Subjects Full Text available with Trip Pro

Cellular and Molecular Mechanisms Underlying Non-Pharmaceutical Ischemic Stroke Therapy in Aged Subjects The incidence of ischemic stroke in humans increases exponentially above 70 years both in men and women. Comorbidities like diabetes, arterial hypertension or co-morbidity factors such as hypercholesterolemia, obesity and body fat distribution as well as fat-rich diet and physical inactivity are common in elderly persons and are associated with higher risk of stroke, increased mortality (...) and disability. Obesity could represent a state of chronic inflammation that can be prevented to some extent by non-pharmaceutical interventions such as calorie restriction and hypothermia. Indeed, recent results suggest that H₂S-induced hypothermia in aged, overweight rats could have a higher probability of success in treating stroke as compared to other monotherapies, by reducing post-stroke brain inflammation. Likewise, it was recently reported that weight reduction prior to stroke, in aged, overweight

2017 International journal of molecular sciences

115. Involving patients and the public in medical and health care research studies: An exploratory survey on participant recruiting and representativeness from the perspective of study authors. Full Text available with Trip Pro

Involving patients and the public in medical and health care research studies: An exploratory survey on participant recruiting and representativeness from the perspective of study authors. Research on patient and public involvement so far concentrates on defining involvement, describing its methods, and analyzing involvement practices in various individual research disciplines. There is little empirical data on the process of and aims for selecting (lay) PPI participants, and to what extend (...) they can and should be representative of the population at large. To explore practices and perceptions on these issues and on future PPI conduct more generally, we sent an electronic survey to authors who published involvement activities as part of their studies in medical and social science journals. We identified such authors with a systematic search of five databases and applied descriptive statistics for analysis. Of those who returned the survey (n = 127 of 315; 40%), most had previously conducted

2019 PLoS ONE

116. Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: anti-platelet therapy

analysis of the health economic impact of end-stage kidney disease (ESKD) in Australia estimated that, at the end of 2007, hospital dialysis cost around $189 million per year. [24] Taken together, CKD is a significant contributor of morbidity and mortality, and represents a major expense to the health care system. Early intervention with appropriate medical therapies is essential to address this public health burden and may reduce the progression of CKD and CV risk by up to 50%. [25] The objective (...) Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: anti-platelet therapy ____________________________________________________________________________________________________________ Early Chronic Kidney Disease July 2012 Page 1 of 9 Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: anti- platelet therapy Date written: July 2012 Author: Richard Phoon, David Johnson GUIDELINES a. We suggest that aspirin therapy should

2013 KHA-CARI Guidelines

117. Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: lipid lowering therapy

is a significant contributor of morbidity and mortality, and represents a major expense to the health care system. Early intervention with appropriate medical therapies is essential to address this public health burden and may reduce the progression of CKD and CV risk by up to 50%. [25] The objective of this guideline is to review currently available evidence in this regard and provide appropriate clinical recommendations. Recommendations in other guidelines, and the evidence underpinning these recommendations (...) Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: lipid lowering therapy ____________________________________________________________________________________________________________ Early Chronic Kidney Disease July 2012 Page 1 of 14 Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: lipid lowering therapy Date written: July 2012 Author: Richard Phoon, David Johnson GUIDELINES a. We recommend that patients with early

2013 KHA-CARI Guidelines

118. Anti-infective therapy of peri-implantitis with adjunctive local drug delivery or photodynamic therapy: 12-month outcomes of a randomized controlled clinical trial. Full Text available with Trip Pro

Anti-infective therapy of peri-implantitis with adjunctive local drug delivery or photodynamic therapy: 12-month outcomes of a randomized controlled clinical trial. The objective of the study is to compare the clinical, microbiological and host-derived effects in the non-surgical treatment of initial peri-implantitis with either adjunctive local drug delivery (LDD) or adjunctive photodynamic therapy (PDT) after 12 months.Forty subjects with initial peri-implantitis, that is, pocket probing (...) . No statistically significant differences (P > 0.05) were observed between groups after 12 months with respect to clinical, microbiological and host-derived parameters.Non-surgical mechanical debridement with adjunctive PDT was equally effective in the reduction of mucosal inflammation as with adjunctive delivery of minocycline microspheres up to 12 months. Adjunctive PDT may represent an alternative approach to LDD in the non-surgical treatment of initial peri-implantitis.© 2013 John Wiley & Sons A/S

2014 Clinical oral implants research Controlled trial quality: uncertain

119. Pharmaceuticals Requiring Companion Diagnostics

Pharmaceuticals Requiring Companion Diagnostics Pharmaceuticals Requiring Companion Diagnostics | CADTH.ca CADTH Document Viewer Pharmaceuticals Requiring Companion Diagnostics Table of Contents Search this document Pharmaceuticals Requiring Companion Diagnostics June 2016 Background and Context The purpose of this Environmental Scan is to provide an overview of the current and projected use of companion diagnostic tests required for the prescription of targeted drug therapies, as well (...) treatment, depending on the intervention and medical condition). Different definitions have been proposed for personalized medicine, including, but not limited to, the following: In the US, the Personalized Medicine Coalition defines personalized medicine as the “tailoring of medical treatment to the individual characteristics of each patient. It does not mean that drugs (or medical devices) are developed to be unique to a patient but rather the ability to classify individuals into subpopulations

2016 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

120. An ensemble of neural models for nested adverse drug events and medication extraction with subwords. Full Text available with Trip Pro

An ensemble of neural models for nested adverse drug events and medication extraction with subwords. This article describes an ensembling system to automatically extract adverse drug events and drug related entities from clinical narratives, which was developed for the 2018 n2c2 Shared Task Track 2.We designed a neural model to tackle both nested (entities embedded in other entities) and polysemous entities (entities annotated with multiple semantic types) based on MIMIC III discharge summaries (...) . To better represent rare and unknown words in entities, we further tokenized the MIMIC III data set by splitting the words into finer-grained subwords. We finally combined all the models to boost the performance. Additionally, we implemented a featured-based conditional random field model and created an ensemble to combine its predictions with those of the neural model.Our method achieved 92.78% lenient micro F1-score, with 95.99% lenient precision, and 89.79% lenient recall, respectively. Experimental

2019 Journal of the American Medical Informatics Association

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>